<DOC>
	<DOCNO>NCT02571257</DOCNO>
	<brief_summary>The purpose study evaluate effect gemcabene LDL-C lipid parameter hypercholesterolemic patient stable dose statin .</brief_summary>
	<brief_title>Efficacy Safety Gemcabene Hypercholesterolemic Patients Stable Statin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Males Females 18 65 year age Baseline LDLC ≥ 130 mg/dL ( 3.4 mmol/L ) If female , postmenopausal surgically menopausal Triglycerides ( TG ) &gt; 400 mg/dL Creatine phosphokinase ( CPK ) &gt; 3 × upper limit normal ( ULN ) Body Mass Index ( BMI ) &gt; 35 kg/m2 Uncontrolled diabetes mellitus ( HbA1c &gt; 10 % ) Renal dysfunction ( blood urea nitrogen [ BUN ] creatinine &gt; 2 × ULN ) Hepatic dysfunction ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 2 × ULN ) Myocardial infarction , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , major cardiovascular event result hospitalization previous month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>